AEON
AEON Biopharma, Inc.1.0300
+0.1660+19.2%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
14.21MP/E (TTM)
0.35Basic EPS (TTM)
2.98Dividend Yield
0%Recent Filings
8-K
8-K
8-K
8-K
ABP-450 biosimilar update
AEON Biopharma released its September 2025 corporate presentation, outlining ABP-450 as a biosimilar to BOTOX targeting the $3B+ U.S. neurotoxin therapeutic market across all 12 indications via extrapolation. With primary structure data due in Q3 2025 and a key FDA BPD Type 2a meeting in Q4, the program leverages global approvals in 69+ countries and scaled manufacturing to address payer costs and boost access. Biosimilars like this promise rapid penetration, yet regulatory hurdles loom large.
10-Q
Q2 FY2025 results
AEON Biopharma posted a Q2 operating loss of $4.3 million, up from a $153.5 million gain last year driven by a $161.2 million drop in contingent consideration fair value, while R&D costs fell 75% year-over-year to $1.1 million as Phase 2 migraine trials wrapped up. For the half-year, net income flipped to $2.5 million from $46.1 million, with operating expenses down 81% in R&D to $1.9 million amid the biosimilar pivot for ABP-450. Cash burn eased to $10.0 million from $16.7 million, bolstered by $18.3 million from a January public offering, leaving $8.4 million in cash against $15.2 million in convertible notes due 2027 at 15.79% interest. Warrant exercises added 10.3 million shares, diluting EPS slightly to $0.31 diluted. Cash lasts into Q4 2025. Yet regulatory hurdles loom large for biosimilar approval.
IPO
Employees
Sector
Industry
ABVC
ABVC Biopharma, Inc.
2.06-0.01
AIBT
Aibotics Inc.
0.00+0.00
ASBP
Aspire Biopharma Holdings, Inc.
0.10-0.00
ATAI
Atai Beckley N.V
4.23+0.09
ATHA
Athira Pharma, Inc.
3.88+0.03
ATHE
Alterity Therapeutics Limited
3.07+0.06
AUPH
Aurinia Pharmaceuticals Inc
15.85+0.16
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
IONS
Ionis Pharmaceuticals, Inc.
78.37-1.39
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12